신경영상 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Neuroimaging Market is set to reach USD 69.0 billion in 2035, growing at a CAGR of 7.1 % from USD 37.3 billion in 2026.

The global neuroimaging market is experiencing substantial growth as healthcare systems increasingly rely on advanced imaging technologies for the diagnosis, monitoring, and treatment of neurological disorders. Neuroimaging encompasses a broad range of technologies used to visualize the structure, function, and activity of the brain, spinal cord, and nervous system. These technologies play a critical role in the management of neurological conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, multiple sclerosis, traumatic brain injuries, brain tumors, and other neurodegenerative disorders.

The growing prevalence of neurological diseases worldwide is one of the primary factors driving market expansion. Aging populations, increasing life expectancy, rising incidence of chronic neurological disorders, and growing awareness regarding early disease detection are creating significant demand for advanced neuroimaging solutions. Healthcare providers increasingly utilize neuroimaging technologies to improve diagnostic accuracy, enable earlier intervention, and support personalized treatment planning.

Technological advancements continue to transform the neuroimaging landscape. Innovations in magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), functional MRI (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG), and hybrid imaging systems are improving image quality, diagnostic precision, and workflow efficiency. The integration of artificial intelligence, machine learning, cloud-based imaging platforms, and advanced image analysis software is further enhancing clinical capabilities and supporting more efficient interpretation of neurological data.

The market is also benefiting from expanding neuroscience research, increasing investments in brain health initiatives, and growing utilization of imaging biomarkers in clinical trials. Pharmaceutical companies, academic institutions, and research organizations rely heavily on neuroimaging technologies to study disease mechanisms, evaluate therapeutic interventions, and identify biomarkers for neurological disorders. As precision medicine and neuroscience research continue to advance, neuroimaging is expected to remain a foundational component of neurological healthcare and research activities.

Market Drivers

Increasing Prevalence of Neurological Disorders

The rising burden of neurological diseases remains a major driver of market growth. Conditions such as Alzheimer's disease, Parkinson's disease, stroke, epilepsy, dementia, multiple sclerosis, and brain tumors affect millions of individuals globally and require advanced diagnostic tools for effective management.

Neuroimaging technologies provide clinicians with detailed insights into brain structure and function, supporting accurate diagnosis and disease monitoring. As neurological disease prevalence continues to increase, demand for advanced imaging procedures is expected to rise significantly.

Growing Emphasis on Early Diagnosis

Healthcare providers increasingly recognize the importance of early detection in improving outcomes for neurological disorders. Many neurological conditions progress gradually and may become difficult to treat once substantial neurological damage has occurred.

Advanced neuroimaging technologies enable clinicians to identify structural and functional abnormalities at earlier stages, supporting timely intervention and improved patient management. This trend is driving adoption across hospitals, specialty clinics, and research institutions.

Advancements in Imaging Technologies

Continuous innovation in imaging equipment is enhancing the capabilities of neuroimaging systems. High-field MRI scanners, hybrid PET/MRI systems, advanced CT technologies, and functional imaging techniques provide more detailed and accurate neurological assessments.

Artificial intelligence-driven image analysis tools are improving workflow efficiency, reducing interpretation times, and increasing diagnostic accuracy. These technological developments are expanding the clinical value of neuroimaging across multiple neurological applications.

Expansion of Neuroscience Research

Global investments in neuroscience research are creating significant opportunities for the neuroimaging market. Researchers increasingly utilize advanced imaging technologies to investigate brain function, disease progression, neural connectivity, and treatment responses.

The growing number of clinical trials focused on neurodegenerative diseases, psychiatric disorders, and neurological therapies is generating sustained demand for sophisticated neuroimaging systems and analytical platforms.

Rising Healthcare Expenditures

Governments and healthcare organizations worldwide are increasing investments in diagnostic infrastructure and advanced medical technologies. Expanding healthcare budgets, hospital modernization programs, and improvements in neurological care services are supporting broader adoption of neuroimaging solutions.

Emerging economies are also investing in advanced imaging capabilities to address growing healthcare demands and improve access to neurological diagnostics.

Market Restraints

High Equipment and Operational Costs

Neuroimaging systems require substantial capital investments and ongoing maintenance expenditures. Advanced MRI, PET, and hybrid imaging systems involve significant acquisition costs, specialized infrastructure requirements, and highly trained personnel.

These financial barriers may limit adoption among smaller healthcare facilities and institutions operating with constrained budgets.

Limited Access in Developing Regions

Many developing countries continue to face challenges related to healthcare infrastructure, imaging equipment availability, and specialist workforce shortages. Limited access to advanced neuroimaging technologies can affect diagnostic capabilities and patient outcomes.

Addressing these disparities requires continued investment in healthcare infrastructure and workforce development.

Regulatory and Reimbursement Challenges

Complex regulatory requirements and varying reimbursement policies can influence market growth. Imaging providers and healthcare facilities must comply with stringent quality standards, safety regulations, and clinical validation requirements.

Reimbursement limitations for advanced imaging procedures may also impact adoption rates in certain healthcare systems.

Technology and Segment Insights

By Imaging Modality

Magnetic resonance imaging (MRI) represents one of the largest segments of the neuroimaging market due to its ability to provide highly detailed anatomical and functional brain images without ionizing radiation. MRI is widely used for diagnosing neurological disorders, monitoring disease progression, and supporting research activities.

Computed tomography (CT) remains an important imaging modality due to its rapid imaging capabilities, accessibility, and effectiveness in emergency neurological assessments such as stroke and traumatic brain injury evaluation.

Positron emission tomography (PET) is increasingly utilized for functional brain imaging and biomarker analysis. PET imaging plays a particularly important role in neurodegenerative disease diagnosis and research applications.

Functional MRI (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG), and hybrid imaging systems continue to gain adoption as healthcare providers seek more comprehensive neurological assessments.

By Application

Neurodegenerative disease diagnosis represents a major application segment. Imaging technologies are extensively utilized for the evaluation of Alzheimer's disease, Parkinson's disease, dementia, and other progressive neurological disorders.

Stroke assessment remains a significant application area due to the critical importance of rapid diagnosis and treatment planning. Advanced neuroimaging enables clinicians to identify affected brain regions and guide therapeutic decisions.

Brain tumor detection, epilepsy evaluation, traumatic brain injury assessment, psychiatric disorder investigations, cognitive function studies, and neurovascular imaging also contribute substantially to market demand.

By End User

Hospitals account for the largest share of the neuroimaging market due to their comprehensive diagnostic capabilities, advanced infrastructure, and high patient volumes. These facilities perform a wide range of neurological imaging procedures and support multidisciplinary care.

Diagnostic imaging centers represent another important segment as demand for specialized neurological imaging services continues to increase. These centers provide access to advanced technologies and expert imaging interpretation.

Research institutions and academic medical centers remain significant users of neuroimaging systems due to extensive neuroscience research activities, clinical trials, and medical education programs.

By Technology

Structural neuroimaging technologies continue to dominate market demand due to their widespread use in routine neurological diagnosis. These techniques provide detailed anatomical information regarding brain structures and pathological abnormalities.

Functional neuroimaging technologies are experiencing strong growth due to increasing interest in brain connectivity, cognitive function, and neural activity assessment. Functional imaging is becoming increasingly important in both clinical and research settings.

Artificial intelligence-enabled imaging platforms are emerging as a major area of innovation, supporting automated image analysis, disease detection, and predictive modeling.

Regional Insights

North America dominates the global neuroimaging market due to advanced healthcare infrastructure, strong research capabilities, high healthcare spending, and widespread adoption of innovative imaging technologies. The region benefits from extensive neuroscience research programs and significant investments in neurological healthcare.

Europe represents a substantial market supported by increasing prevalence of neurological disorders, strong healthcare systems, and growing investments in diagnostic technologies. Government-supported research initiatives and healthcare modernization efforts continue to support market growth.

Asia Pacific is expected to witness the fastest growth during the forecast period. Rising healthcare expenditures, expanding hospital infrastructure, increasing awareness of neurological diseases, and growing adoption of advanced imaging technologies are creating substantial opportunities across China, Japan, India, South Korea, and Southeast Asia.

Latin America and the Middle East & Africa are gradually expanding their neuroimaging capabilities as healthcare infrastructure improves and access to advanced diagnostic technologies increases.

Competitive and Strategic Outlook

The neuroimaging market is characterized by continuous technological innovation and strong competition among imaging equipment manufacturers, healthcare technology providers, software developers, and diagnostic solution companies. Market participants are investing heavily in advanced imaging systems, artificial intelligence integration, cloud-based imaging platforms, and precision diagnostic technologies.

Strategic collaborations among healthcare providers, research institutions, technology companies, and pharmaceutical organizations are accelerating innovation and expanding clinical applications. Companies are increasingly focused on improving image quality, reducing scan times, enhancing workflow efficiency, and delivering comprehensive neurological imaging solutions.

Future competition is expected to center on artificial intelligence-driven diagnostics, hybrid imaging technologies, advanced biomarker identification, and personalized neurological care platforms. Organizations that successfully combine technological innovation with clinical effectiveness and operational efficiency are likely to strengthen their market positions.

Conclusion

The global neuroimaging market is positioned for sustained growth as healthcare systems increasingly prioritize early diagnosis, precision medicine, and advanced neurological care. Rising prevalence of neurological disorders, expanding neuroscience research activities, technological advancements in imaging modalities, and growing healthcare investments are expected to drive market expansion. While challenges related to costs, infrastructure requirements, and workforce limitations remain, ongoing innovation in imaging technologies and artificial intelligence will continue to strengthen the role of neuroimaging in modern neurological healthcare and research.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Global Neuroimaging Market Scope and Objectives
• 1.2 Key Market Insights and Strategic Highlights
• 1.3 Imaging Procedure Volume and Adoption Trends
• 1.4 Market Growth Outlook and Revenue Forecast
• 1.5 Strategic Conclusions

2. Global Neuroimaging Market Overview

• 2.1 Definition and Scope of Global Neuroimaging Market
• 2.2 Global Neuroimaging Market Size Analysis 2021-2024
• 2.3 Global Neuroimaging Market Size Forecast 2025-2035
• 2.4 Market Drivers
  • 2.4.1 Rising Prevalence of Neurological Disorders
  • 2.4.2 Growing Demand for Early and Accurate Diagnosis
  • 2.4.3 Technological Advancements in Brain Imaging Systems
  • 2.4.4 Increasing Utilization in Neuroscience Research and Drug Development
• 2.5 Market Restraints
  • 2.5.1 High Equipment and Installation Costs
  • 2.5.2 Limited Availability of Advanced Imaging Infrastructure
  • 2.5.3 Regulatory and Reimbursement Challenges
• 2.6 Market Opportunities
  • 2.6.1 Expansion of AI-Enabled Neuroimaging Solutions
  • 2.6.2 Growth of Functional and Molecular Brain Imaging
  • 2.6.3 Emerging Market Healthcare Infrastructure Development
• 2.7 Global Neuroimaging Market Segmentation
  • 2.7.1 By Imaging Modality
    • 2.7.1.1 Magnetic Resonance Imaging (MRI)
    • 2.7.1.2 Computed Tomography (CT)
    • 2.7.1.3 Positron Emission Tomography (PET)
    • 2.7.1.4 Single Photon Emission Computed Tomography (SPECT)
    • 2.7.1.5 Magnetoencephalography (MEG)
    • 2.7.1.6 Functional Near-Infrared Spectroscopy (fNIRS)
    • 2.7.1.7 Electroencephalography (EEG)-Based Neuroimaging
  • 2.7.2 By Application
    • 2.7.2.1 Neurodegenerative Diseases
    • 2.7.2.2 Stroke and Cerebrovascular Disorders
    • 2.7.2.3 Epilepsy
    • 2.7.2.4 Brain Tumors
    • 2.7.2.5 Traumatic Brain Injury
    • 2.7.2.6 Psychiatric Disorders
    • 2.7.2.7 Neuroscience Research
  • 2.7.3 By End User
    • 2.7.3.1 Hospitals
    • 2.7.3.2 Diagnostic Imaging Centers
    • 2.7.3.3 Academic and Research Institutes
    • 2.7.3.4 Specialty Neurology Centers
  • 2.7.4 By Technology
    • 2.7.4.1 Structural Neuroimaging
    • 2.7.4.2 Functional Neuroimaging
    • 2.7.4.3 Molecular Neuroimaging

3. Neurological Disease Epidemiology and Imaging Demand Analysis

• 3.1 Global Burden of Neurological Disorders
• 3.2 Alzheimer's Disease and Dementia Epidemiology
• 3.3 Parkinson's Disease Epidemiology
• 3.4 Stroke Burden and Imaging Requirements
• 3.5 Brain Tumor Incidence and Diagnostic Trends
• 3.6 Forecast of Neuroimaging Procedure Volumes

4. Disease and Unmet Need Analysis

• 4.1 Need for Early Detection of Neurological Disorders
• 4.2 Challenges in Differential Diagnosis of Brain Diseases
• 4.3 Need for Precision Imaging Biomarkers
• 4.4 Limitations of Conventional Imaging Approaches
• 4.5 Unmet Need in Low-Resource Healthcare Settings

5. Technology and Innovation Landscape

• 5.1 Evolution of Neuroimaging Technologies
• 5.2 Structural Neuroimaging Technology Analysis
• 5.3 Functional Neuroimaging Technology Analysis
• 5.4 Molecular Imaging Technology Analysis
• 5.5 Artificial Intelligence and Machine Learning Integration
• 5.6 Imaging Biomarker Development Trends
• 5.7 Comparative Performance and Diagnostic Accuracy Analysis

6. Clinical and Commercial Intelligence

• 6.1 Clinical Guideline Positioning
• 6.2 Neuroimaging Utilization Trends
• 6.3 Comparative Effectiveness Benchmarking
• 6.4 Pricing Trends and Reimbursement Dynamics
• 6.5 Market Share Analysis by Imaging Modality
• 6.6 Hospital Procurement and Purchasing Trends
• 6.7 Lifecycle Management Strategies
• 6.8 Regulatory Approval and Compliance Analysis

7. Product Benchmarking

• 7.1 MRI System Benchmarking
• 7.2 CT Neuroimaging System Benchmarking
• 7.3 PET and SPECT Neuroimaging Benchmarking
• 7.4 Functional Neuroimaging Platform Benchmarking
• 7.5 AI-Enabled Neuroimaging Software Benchmarking
• 7.6 Competitive Differentiation Analysis

8. Market Forecast and Risk Analysis

• 8.1 Revenue Forecast Modeling
• 8.2 Neuroimaging Procedure Volume Forecast
• 8.3 Technology Adoption Forecast
• 8.4 Pricing and Reimbursement Sensitivity Analysis
• 8.5 Key Risk Factors
  • 8.5.1 Regulatory and Compliance Risks
  • 8.5.2 Capital Equipment Investment Risks
  • 8.5.3 Reimbursement and Funding Risks
  • 8.5.4 Technology Obsolescence Risks
• 8.6 Sensitivity and Scenario Analysis

9. Competitive Landscape

• 9.1 Market Share by Manufacturer
• 9.2 Competitive Positioning of Neuroimaging Technologies
• 9.3 Innovation and Patent Landscape Analysis
• 9.4 Product Portfolio Breadth Analysis
• 9.5 Strategic Collaborations and Partnerships
• 9.6 Mergers, Acquisitions, and Investment Activity

10. Geographic Analysis

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 Latin America
• 10.5 Middle East and Africa

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Company Profiles

• 12.1 GE HealthCare Technologies Inc.
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Product Portfolio
  • 12.1.4 Recent Developments
• 12.2 Siemens Healthineers AG
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Product Portfolio
  • 12.2.4 Recent Developments
• 12.3 Koninklijke Philips N.V.
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Product Portfolio
  • 12.3.4 Recent Developments
• 12.4 Canon Medical Systems Corporation
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Product Portfolio
  • 12.4.4 Recent Developments
• 12.5 Fujifilm Holdings Corporation
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Product Portfolio
  • 12.5.4 Recent Developments
• 12.6 Bruker Corporation
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Product Portfolio
  • 12.6.4 Recent Developments
• 12.7 United Imaging Healthcare Co., Ltd.
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Product Portfolio
  • 12.7.4 Recent Developments
• 12.8 Shimadzu Corporation
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Product Portfolio
  • 12.8.4 Recent Developments
• 12.9 NeuroLogica Corporation
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Product Portfolio
  • 12.9.4 Recent Developments
• 12.10 Brainlab AG
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Product Portfolio
  • 12.10.4 Recent Developments

13. Future Outlook and Strategic Insights

• 13.1 Expansion of AI-Powered Neuroimaging Solutions
• 13.2 Growth of Molecular and Functional Brain Imaging
• 13.3 Increasing Role of Neuroimaging in Precision Neurology
• 13.4 Opportunities in Emerging Markets and Research Applications
• 13.5 Strategic Recommendations

14. Methodology and Data Framework

• 14.1 Data Sources
• 14.2 Epidemiology and Imaging Utilization Modeling Approach
• 14.3 Market Sizing and Forecasting Methodology
• 14.4 Competitive Benchmarking Framework
• 14.5 Assumptions and Limitations